🔗 Share this article

As the US proceeds with historic revisions to its vaccine recommendations, a particular individual appears unexpectedly: Høeg, a US-based physician and public health researcher who initially gained attention by casting doubt on COVID-19 shots in the pandemic and has zeroed in on alleged fatalities after Covid vaccination in her recent time at the US Food and Drug Administration (FDA).

Scheduled Changes to Childhood Immunization Program

Public health authorities had intended to unveil major revisions to the pediatric vaccine schedule earlier this month, synchronizing the US with the Danish national calendar, according to reports – a substantial departure that would place the US at odds with much of the world with no evidence for public health gain. This reveal has been delayed until the coming year.

Rather than the director of the vaccine center, Tracy Beth Høeg is set to speak at the gathering. She was recently named interim head of the FDA’s CDER, the fifth individual to run the division this year.

A Shift at the FDA

This interim role may indicate a closer partnership between the drug and vaccine centers as Høeg and Prasad consolidate power at the FDA – and it points to a increased emphasis upon dismantling already-approved vaccines at the FDA.

Dr. Høeg has often pushed for ending specific pediatric vaccine recommendations in the US in order to be more similar to Denmark's approach, a society with universal health coverage and a citizenry about the size of the state of Wisconsin.

In her initial comments, she has persisted in emphasizing on vaccination policy – typically the domain of Prasad, head of the FDA’s vaccine center – instead of drug regulation.

Doubts Over Expertise

Høeg has no apparent experience in medication creation, approval processes or administrative roles, which has been typical for past leaders of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the FDA chief and the vaccine center since March.

“It seems she lacks to have the requisite experience” for leading the pharmaceutical oversight division, said Dr. Jonathan Howard. “She’s never run a scientific study. She lacks experience in managing a major agency. She has no expertise in drug approvals.”

Past directors of the center would “be deeply familiar with regulatory frameworks and the research of medication creation”, noted Dr. Janet Woodcock. “Clearly, she doesn’t have the sort of resume that prior appointees who ran CBER have had.”

This division has an immense range of responsibilities at the agency, Woodcock emphasized.

“Many people just zeroes in on the novel medication approvals, but the off-patent medication office clears numerous off-brand pharmaceuticals. There’s a biosimilars division, non-prescription drug unit and other areas, and every single one have to be managed,” Woodcock said. “The area you overlook, that’s the thing that I always told people is going to come back to haunt you.”

There is also, a significant leadership aspect to the job, which manages in excess of 5,000 employees. “It is a enormous administrative position, if you execute it properly,” Woodcock said.

Agency Reaction and Contentious Policies

In response to questions about Høeg’s fitness for the role and whether this appointment indicates increased cooperation among regulatory chiefs on vaccines, a spokesperson responded that the “questions rely on inaccurate premises”.

“Her resume matches the duties of her position,” the official stated, pointing to the months Dr. Høeg spent guiding the FDA commissioner on “medication safety and oversight research, including computerized risk analysis and vaccine surveillance”.

As acting director, Dr. Høeg assumes responsibility for the agency head's new expedited review system, a contentious expedited therapy clearance system that allegedly concerned her preceding directors. “By what process are these drugs being chosen for this fast-track system? Who makes the calls?” Howard questioned. “There is a lot of confidentiality happening at the agency right now.”

Broadly speaking, he stated, “the agency looks to be trending towards less stringent regulations of all drugs, with the exception of immunizations.”

Public Past Work on Vaccines

Concerning immunizations, Dr. Høeg has a clearer, if concerning, past, Howard have noted. She authored a research paper using unverified public submissions to determine the incidence of heart inflammation after COVID-19 vaccination. She consulted for the Florida surgeon general Joseph Ladapo, who reportedly have changed statistics to indicate Covid vaccinations are pose a greater threat than they are.

Part of her “wish list” for the incoming administration included revising guidelines for novel immunizations and discontinuing “optional” immunizations, she stated after the election on a audio program. At the agency, Dr. Høeg has according to sources proposed barring young men from getting COVID-19 vaccines.

“She’s an thorough true believer who starts off with her conclusions and reverse-engineers to retrofit the evidence in a highly misleading, dishonest manner,” Howard stated.

Taking Control and a “Campaign of Retribution”

Høeg joined fellow skeptics, {like|